iBio, Inc. Statistics

Total Valuation

iBio, Inc. has a market cap or net worth of $14.71 million. The enterprise value is $14.23 million.

Market Cap	14.71M
Enterprise Value	14.23M

Important Dates

The last earnings date was Friday, May 2, 2025, before market open.

Earnings Date	May 2, 2025
Ex-Dividend Date	n/a

Share Statistics

iBio, Inc. has 16.52 million shares outstanding. The number of shares has increased by 376.23% in one year.

Current Share Class	16.52M
Shares Outstanding	16.52M
Shares Change (YoY)	+376.23%
Shares Change (QoQ)	+7.99%
Owned by Insiders (%)	2.60%
Owned by Institutions (%)	15.78%
Float	15.84M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	23.84
Forward PS	145.76
PB Ratio	0.87
P/TBV Ratio	2.82
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	37.94
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.12, with a Debt / Equity ratio of 0.38.

Current Ratio	1.12
Quick Ratio	0.92
Debt / Equity	0.38
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-73.74

Financial Efficiency

Return on equity (ROE) is -90.83% and return on invested capital (ROIC) is -35.91%.

Return on Equity (ROE)	-90.83%
Return on Assets (ROA)	-30.35%
Return on Invested Capital (ROIC)	-35.91%
Return on Capital Employed (ROCE)	-122.67%
Revenue Per Employee	$23,438
Profits Per Employee	-$1.31M
Employee Count	16
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -64.33% in the last 52 weeks. The beta is 0.94, so iBio, Inc.'s price volatility has been similar to the market average.

Beta (5Y)	0.94
52-Week Price Change	-64.33%
50-Day Moving Average	1.41
200-Day Moving Average	2.55
Relative Strength Index (RSI)	43.05
Average Volume (20 Days)	510,326

Short Selling Information

The latest short interest is 656,763, so 3.98% of the outstanding shares have been sold short.

Short Interest	656,763
Short Previous Month	925,508
Short % of Shares Out	3.98%
Short % of Float	4.15%
Short Ratio (days to cover)	0.31

Income Statement

In the last 12 months, iBio, Inc. had revenue of $375,000 and -$20.99 million in losses. Loss per share was -$2.32.

Revenue	375,000
Gross Profit	375,000
Operating Income	-16.81M
Pretax Income	n/a
Net Income	-20.99M
EBITDA	-16.02M
EBIT	-16.81M
Loss Per Share	-$2.32

Full Income Statement

Balance Sheet

The company has $4.96 million in cash and $4.32 million in debt, giving a net cash position of $639,000 or $0.04 per share.

Cash & Cash Equivalents	4.96M
Total Debt	4.32M
Net Cash	639,000
Net Cash Per Share	$0.04
Equity (Book Value)	11.38M
Book Value Per Share	1.13
Working Capital	663,000

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$15.54 million and capital expenditures -$225,000, giving a free cash flow of -$15.77 million.

Operating Cash Flow	-15.54M
Capital Expenditures	-225,000
Free Cash Flow	-15.77M
FCF Per Share	-$0.95

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-4,483.47%
Pretax Margin	-4,389.33%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

iBio, Inc. does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-376.23%
Shareholder Yield	-376.23%
Earnings Yield	-141.20%
FCF Yield	-106.06%

Analyst Forecast

The average price target for iBio, Inc. is $4.87, which is 446.88% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$4.87
Price Target Difference	446.88%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-31.30%

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on November 29, 2023. It was a reverse split with a ratio of 0.05:1.

Last Split Date	Nov 29, 2023
Split Type	Reverse
Split Ratio	0.05:1

Scores

iBio, Inc. has an Altman Z-Score of -24.99 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-24.99
Piotroski F-Score	2